<DOC>
	<DOCNO>NCT02846935</DOCNO>
	<brief_summary>The purpose study evaluate well study drug work safety oral decitabine patient refractory relapse lymphoid malignancy . The decitabine give low dose use approve use . It also give another drug , tetrahydrouridine ( THU ) , improve exposure lymphoma cell decitabine .</brief_summary>
	<brief_title>p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine Refractory/Relapsed Lymphoid Malignancies</brief_title>
	<detailed_description>Primary objective : To determine objective response rate oral THU-Dec patient 3 separate biologic subset refractory/relapsed lymphoid malignancy : 1 . T-cell lymphoma , 2 . Aggressive B cell lymphoma , 3. indolent B-cell lymphoma . Secondary objective : ( ) To evaluate toxicity oral THU-Dec patient ; ( ii ) To evaluate hypothesis regard mechanism resistance predictive biomarkers .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Tetrahydrouridine</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Histologically cytologicallyproven T Bcell lymphoma Subjects must receive 1 prior therapy disease stable disease progressive disease base upon criterion Revised Response Criteria Malignant Lymphoma78 , intolerable toxicity preclude therapy prior regimen Subjects must measurable disease per Revised Response Criteria Malignant Lymphoma78 ECOG performance status 0 2 Adequate organ function define follow criterion : Serum aspartate transaminase ( AST ; serum glutamic oxaloacetic transaminase [ SGOT ] ) serum alanine transaminase ( ALT ; serum glutamic pyruvic transaminase [ SGPT ] ) ≤ 2.5 x laboratory upper limit normal ( ULN ) Total serum bilirubin ≤ 2.0 x ULN ( except Gilbert 's disease ) Absolute neutrophil count ( ANC ) ≥ 1500/uL Platelets ≥ 50,000/uL Hemoglobin ≥ 8.0 g/dL ( transfusion permit ) Serum calcium ≤ 12.0 mg/dL Serum Creatinine ≤ 3.0 mg/dL Patients history CNS lymphoma enrol CNS disease control therapy minimum 4 week . Brain MRI require eligibility . Subjects must ability understand willingness sign write informed consent document . Life expectancy ≤ 4 month judgment treat clinician Known human immunodeficiency virus ( HIV ) acquire immunodeficiency syndrome ( AIDS ) relate illness ( HIVpositive subject combination antiretroviral therapy ineligible potential pharmacokinetic interaction oral THUDec . Appropriate study undertaken subject receive combination antiretroviral therapy indicate . Pregnancy breastfeed ( pregnant breastfeed woman exclude study oral THUDec potential teratogenic abortifacient effect . Because unknown , potential , risk adverse event nurse infant secondary treatment mother oral THUDec , breastfeed discontinue mother treated oral THUDec . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration , may interfere interpretation study result , judgment investigator would make patient inappropriate entry study . Receiving investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>p16/CDKN2A</keyword>
	<keyword>TP53</keyword>
	<keyword>THU</keyword>
	<keyword>Decitabine</keyword>
	<keyword>Tetrahydrouridine</keyword>
	<keyword>DEC</keyword>
</DOC>